Aquapharm Biodiscovery, a marine biotechnology company, has signed a research agreement with Albany Molecular Research (AMRI) to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s collection of marine microorganisms. AMRI will screen Aquapharm’s library against Gram-negative and Gram-positive bacteria and an undisclosed anti-inflammatory target, and will isolate and elucidate the structures of novel hits. Aquapharm retains all ...